Trial Condition(s):

Castration-Resistant Prostatic Cancer

Pain evaluation in Radium-223 treated castration resistant prostate cancer patients with bone metastases (PARABO)

Bayer Identifier:

17550

ClinicalTrials.gov Identifier:

NCT02398526

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.

Inclusion Criteria
- Adult male patients diagnosed with CRPC with symptomatic bone metastases without known visceral metastases 
 - Decision to initiate treatment with Radium-223 was made as per investigator’s routine treatment practice
Exclusion Criteria
- Patients participating in an investigational program with interventions outside of routine clinical practice or participating in another observational study with Xofigo

Trial Summary

Enrollment Goal
363
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Germany

Status
Completed
 

Trial Design